[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"trial:NCT07388355":3,"trial-entities:NCT07388355":99,"trial-summary:NCT07388355":104},{"id":4,"nct_id":4,"org_study_id":5,"brief_title":6,"official_title":7,"overall_status":8,"completion_date":9,"status_verified_date":10,"last_update_date":11,"start_date":12,"sponsor_name":13,"lead_sponsor_class":14,"has_dmc":15,"brief_summary":16,"detailed_description":17,"conditions":18,"keywords":23,"study_type":28,"primary_purpose":29,"phases":30,"enrollment_info":32,"interventions":35,"primary_outcomes":43,"secondary_outcomes":51,"sex":52,"minimum_age":53,"maximum_age":54,"healthy_volunteers":55,"eligibility_criteria":56,"std_ages":68,"locations":71,"central_contacts":87,"overall_officials":93,"references":97,"see_also_links":98},"NCT07388355","CLN 0001","A Usability Study of a Multi-channel ECG Monitoring Device","WearLinq eWave Patch Study","RECRUITING","2027-07-31","2026-07","2026-07-21","2026-07-06","Wearlinq","INDUSTRY",false,"This study it to evaluate the usability of the WearLinq eWave patch in a general adult population.","Once eligibility is determined, participants will receive and apply the WearLinq patch for 7 consecutive days (or until an endpoint is met). A subset of subjects will be asked to participate in an Extended Use Cohort (30 days).",[19,20,21,22],"Healthy Adult Participants","Heart Disease","Arrythmia","Cardiac",[24,25,26,27],"Electrocardiogram","ECG","EKG","Cardiac diagnostic","INTERVENTIONAL","SUPPORTIVE_CARE",[31],"NA",{"count":33,"type":34},500,"ESTIMATED",[36],{"type":37,"name":38,"description":39,"armGroupLabels":40},"DEVICE","eWave Patch","This device is a wearable multi-channel ECG monitoring device for continuous cardiac rhythm tracking.",[41,42],"7 Day Study","Extended Use Cohort",[44,48],{"measure":45,"description":46,"timeFrame":47},"Wear Duration","Days of use until one of the following is reached: patch no longer adheres, signal loss, voluntary removal, or 7 days is achieved","7 Days",{"measure":49,"description":50,"timeFrame":47},"Adverse Events","Incidences of self-reported adverse events for the duration of the study",[],"ALL","18 Years",null,true,{"inclusion":57,"exclusion":61,"raw_text":67},[58,59,60],"Adult \\>18 years old and able to consent","Capable of using a smartphone app","Willing to shave patch area if needed",[62,63,64,65,66],"Planning to undergo an MRI during the study period","Known allergic reaction to adhesives or hydrogels or with family history of adhesive skin allergies, or any other dermatological conditional that could confound placement or results","Presence of pacemaker, ICD or other implanted electronic devices","Open wounds, lesions or infected or inflamed areas of skin at the placement site (left-center of chest\u002Fsternum)","Pregnant or intending to become pregnant during the course of the study","Inclusion Criteria:\n\n* Adult \\>18 years old and able to consent\n* Capable of using a smartphone app\n* Willing to shave patch area if needed\n\nExclusion Criteria:\n\n* Planning to undergo an MRI during the study period\n* Known allergic reaction to adhesives or hydrogels or with family history of adhesive skin allergies, or any other dermatological conditional that could confound placement or results\n* Presence of pacemaker, ICD or other implanted electronic devices\n* Open wounds, lesions or infected or inflamed areas of skin at the placement site (left-center of chest\u002Fsternum)\n* Pregnant or intending to become pregnant during the course of the study",[69,70],"ADULT","OLDER_ADULT",[72],{"facility":73,"status":8,"city":74,"state":75,"zip":76,"country":77,"contacts":78,"geoPoint":84},"ABio Clinical Research Partners","New London","North Carolina","28127","United States",[79],{"name":80,"role":81,"phone":82,"email":83},"Andrea Brown, MS","CONTACT","408-881-2611","wearlinqstudy@abioclinical.com",{"lat":85,"lon":86},35.4432,-80.21922,[88,90],{"name":80,"role":81,"phone":82,"email":89},"abrown@abioclinical.com",{"name":91,"role":81,"email":92},"Chris Daniel","chris@wearlinq.com",[94],{"name":91,"affiliation":95,"role":96},"WearLinq, Inc.","STUDY_DIRECTOR",[],[],{"nct_id":4,"conditions":100,"biomarkers":103},[101,19,102],"Arrhythmia","Heart Disorder",[],{"nct_id":4,"found":55,"summary":105,"prompt_version":115},{"design":106,"status":107,"heading":108,"summary":109,"follow_up":110,"word_count":111,"commitments":112,"compensation":113,"drugs_mentioned":114},"This is an interventional study planning to enroll 500 adult participants. It is evaluating the usability of a multi-channel ECG monitoring device.","completed","Usability Study of the eWave Patch for Heart Monitoring","This study is testing the WearLinq eWave patch, a wearable device that continuously tracks your heart rhythm (ECG monitoring). Researchers want to see how easy and effective the eWave patch is for adults, including those with heart disease or irregular heartbeats (arrhythmia). You might be able to join if you are an adult over 18, can use a smartphone app, and are willing to shave the area where the patch will be placed. The main goals are to measure how long people wear the patch and to track any side effects over 7 days. The current recruitment status is unclear, but the study plans to enroll 500 participants.","The primary endpoints are measured at 7 days after starting the study.",108,"You would apply the WearLinq patch and wear it for 7 consecutive days. A smaller group might wear it for 30 days.","Not stated in the trial record.",[38],"v2"]